IRIS

N-Nitrosodiphenylamine

CASRN 86-30-6

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (10 pp, 102 K)
Not assessed under the IRIS Program.

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (10 pp, 102 K)
Not assessed under the IRIS Program.

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (10 pp, 102 K) last updated: 03/31/1987

WOE Characterization Framework for WOE Characterization
B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Increased incidence of bladder tumors in male and female rats and reticulum cell sarcomas in mice, and structural relationship to carcinogenic nitrosamines
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (10 pp, 102 K)

Oral Slope Factor: 4.9 x10 -3 per mg/kg-day
Drinking Water Unit Risk: 1.4 x10 -7 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Urinary
Tumor type(s): Transitional cell carcinoma of the bladder (NCI, 1979)



Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (10 pp, 102 K)

Not Assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.